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The state of the art in text mining and natural language processing
for pharmacogenomicsPharmacogenomics researchers need high quality information
about the genetic modulators of drug responses. Although Phar-
mGKB (the Pharmacogenomics Knowledge Base, http://www.phar-
mgkb.org/) [1] and other public resources provide such knowledge,
most of it remains within the free text of scientiﬁc articles and bio-
medical reports. It is crucial to provide Natural Language Process-
ing (NLP) tools to extract and encode published facts to support the
design of new experiments and the discovery of new knowledge in
pharmacogenomics [2].
Most pharmacogenomics knowledge occurs in the form of ter-
nary relationships that occur between (i) a drug treatment, (ii) a
genetic variant, and (iii) a drug response. Information extraction
in pharmacogenomics has primarily focused on the binary rela-
tionships that comprise parts of this triad. This special section of
JBI presents recent progress in NLP in support of pharmacogenom-
ics. Some of the work was presented at a symposium dedicated to
this topic at the annual Paciﬁc Symposium on Biocomputing in
2010 (http://www.psb.stanford.edu/), but other articles were con-
tributed in response to an open call for papers for this journal.
The last decade has witnessed great progress in NLP applied to
the general ﬁeld of molecular biology. NLP technologies can create
gene and protein networks that are useful for systems biology. The
ﬁeld has been spurred by international challenges or ‘‘shared
tasks’’ that provide comparative evaluations, under controlled cir-
cumstances, of different approaches [3,4]. Organizers of these com-
petitions create annotated corpora, reference vocabularies, and
evaluation metrics that guide participants as they test, train and
tune their approaches. These resources have improved for each
competition, and have allowed advances to be quantiﬁed. Similar
evaluations may be useful for pharmacogenomics in order to cata-
lyze and document similar progress.
At the same time, researchers in translational bioinformatics [5]
have used NLP with marked success. For example, Campillos et al.
extracted drug side effect information from drug labels (also
known as package inserts) to compute similarities of side effects
and to infer whether two drugs share a target [6]. The authors
made several in silico predictions and validated 11 novel drug-tar-
get relationships in vitro. Percha et al. used a random forest classi-
ﬁer, trained with drug-gene interactions extracted from the
literature, to study drug-drug interactions [7]. On the basis of tex-
tual features extracted from articles, the classiﬁer succeeded in
predicting novel drug-drug interactions.
The eight articles in this special section highlight recent suc-
cesses in applying NLP to key tasks within pharmacogenomics,1532-0464 2012 Published by Elsevier Inc.
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Open access under CC BY-NC-ND license.with the goal of providing reliable tools to support translational
bioinformatics.
The ﬁrst ﬁve articles describe approaches to extracting relevant
pharmacogenomics relationships from the literature. The last three
articles describe the evaluation and the construction of new re-
sources for future research in pharmacogenomics NLP, especially
the creation of new annotated corpora.
The article by R. Xu and Q. Wang demonstrates the extraction of
drug-gene relationships from text [8]. Their extraction method rec-
ognizes exact mentions of drugs and genes occurring simulta-
neously in sentences. Importantly, they demonstrate the
feasibility of performing this extraction on all MEDLINE abstracts,
processing 100 million sentences (grouped in 20 million abstracts)
using a cloud-based named entity recognizer. The authors demon-
strate that the precision and F1 measures obtained by their ap-
proach increase impressively (from 0.11 to 0.345 for the
precision and from 0.201 to 0.402 for the F1 measure) when the
extraction is done only from sentences where one gene-drug rela-
tionship is present.
The article by Rance et al. differs from the ﬁrst in that the infor-
mation extraction is focused on the relationship between drugs
and gene variants instead of genes more generally [9]. Features
of genetic variants such as their position in the sequence are iden-
tiﬁed using regular expressions and subsequently compared to the
entries within dbSNP in order to map the variants to standard
identiﬁers. The authors use the drug-variant relationships manu-
ally curated in PharmGKB to evaluate the recall of their approach
(0.33 on a corpus of 104 MEDLINE articles) and to compare it to
competing approaches.
Thenextarticle, byHakenbergetal.,employsanexhaustive infor-
mation extraction approach to a corpus of 179,935 articles with the
goal of automatically populating a database of twelve different rela-
tionship types among nine different entity types (genes, drugs, dis-
eases, adverse effects, mutations, refSNP, alleles, population and
frequency) [10]. The method uses distinct adapted tools for the rec-
ognition of each entity type (e.g., BANNER for genes [11], Mutation-
Finder for mutations [12], etc.) and combines seven methods for
relation extraction, from simple co-occurrence to syntactic parse
trees. The resulting resource contains 233,964 relationships ex-
tractedwith a precision of 0.48–0.84 and a recall of 0.73–1, depend-
ing on the type of relationship. The full set of resulting relationships
between entities is presented in a new database, called SNPshot.
The next two articles explore the feasibility of using manually
curated relationships within PharmGKB as a gold standard for
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ing new relations. Rinaldi et al. adapted their OntoGene tool for
the extraction of protein–protein interactions to the extraction
of pharmacogenomics relations. The authors evaluate the
performance of their tool using metrics from the BioCreative
shared task, and using PharmGKB gene-drug relationships as a gold
standard [13]. The results are important because they provide an
available benchmark for extracting pharmacogenomics relation-
ships.
Pakhomov et al. take advantage of the PharmGKB labels of po-
sitive and negative relationships between drugs and genes to cre-
ate a machine learning system to predict drug-gene relationships
[14]. The authors extract textual features (words or groups of
two words) from articles where relationships have been manually
curated, and subsequently train a Support Vector Machine (SVM)
to distinguish text that mentions positive associations from text
that does not. When a new abstract that mentions a drug and a
gene is provided to the SVM, it classiﬁes the pair as likely being re-
lated or unrelated. The paper identiﬁes several candidate gene tar-
gets not mentioned in PharmGKB and concludes that the existing
PharmGKB corpus can be used to predict novel pharmacogenomic
relationships.
The ﬁrst of the three articles dealing with the evaluation and
construction of new resources, by Li and Lu, searches for pharmac-
ogenomics knowledge outside of MEDLINE by focusing on the
93,661 clinical trial records included in ClinicalTrials.gov [15].
The lexicons of PharmGKB are used to recognize records containing
a gene and a drug. Manual evaluation of the approach shows a pre-
cision of 0.74 and demonstrates that ClinicalTrials.gov is a rich
source of known and novel pharmacogenomic relationships.
The last two papers of the special section describe the develop-
ment of two corpora manually annotated with drug-disease-gene
relationships and drug-adverse effect relationships. The corpus
developed by Van Mulligen et al. is the EU-ADR Corpus [16]. It is
made of 300 MEDLINE abstracts with annotated relationships
among drugs, disorders, and targets. The entities were initially
annotated with a named entity recognition system, and then cor-
rected and completed by three annotators. Relationships were pro-
posed to annotators when two entities co-occur in a sentence;
annotators evaluate the relationship, associate it with a type (tar-
get-disease, target-drug or target-disease) and a level of certainty
(positive, negative or speculative). Only 1037 of 2436 annotated
relationships are ultimately approved by a group of three curators.
The second corpus, described by Gurulingappa et al., named ADE, is
much larger (2972 documents). It focuses speciﬁcally on drug-ad-
verse effect and drug-dosage relationships [17]. Three individuals
annotate MEDLINE case reports manually at the sentence level.
In the end the resource contains 6821 drug-adverse event relation-
ships. The authors use the resulting annotations to train classiﬁers
that distinguish sentences mentioning drug-adverse event rela-
tionships. They achieve a precision in the range of 0.75 and 0.91.
Both of these corpora, ADR-EU and ADE, will be of great help in
the development and evaluation of future information extraction
systems.
Even without the current exponential increase in the rate of sci-
entiﬁc publications, manual curation without machine assistance
is demonstrably not capable of populating pharmacogenomics dat-
abases [19]. It is notable that when the call for papers for the ﬁrst
(in 2010) Paciﬁc Symposium on Biocomputing workshop on the
extraction of gene-drug-disease relationship from text [18] was
published, there were no annotated corpora and no properly eval-
uated gold standards for pharmacogenomic NLP. It is hoped that
the material presented in this special section will further catalyze
the development of improved and efﬁcient NLP systems and enable
the emergence of a new set of NLP challenges relevant to the crit-
ical ﬁeld of personalized medicine and pharmacogenomics.References
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